494 related articles for article (PubMed ID: 25263215)
21. Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus.
Shaddinger BC; Soffer J; Vlasakakis G; Shabbout M; Weston C; Nino A
Diabetes Res Clin Pract; 2019 Jun; 152():125-134. PubMed ID: 31004676
[TBL] [Abstract][Full Text] [Related]
22. Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial.
Yabe D; Eto T; Shiramoto M; Irie S; Murotani K; Seino Y; Kuwata H; Kurose T; Seino S; Ahrén B; Seino Y
Diabetes Obes Metab; 2017 Mar; 19(3):442-447. PubMed ID: 27800649
[TBL] [Abstract][Full Text] [Related]
23. Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus.
Davis PN; Ndefo UA; Oliver A; Payton E
Am J Health Syst Pharm; 2015 Jul; 72(13):1097-103. PubMed ID: 26092960
[TBL] [Abstract][Full Text] [Related]
24. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Hernandez AF; Green JB; Janmohamed S; D'Agostino RB; Granger CB; Jones NP; Leiter LA; Rosenberg AE; Sigmon KN; Somerville MC; Thorpe KM; McMurray JJV; Del Prato S;
Lancet; 2018 Oct; 392(10157):1519-1529. PubMed ID: 30291013
[TBL] [Abstract][Full Text] [Related]
25. Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide.
Brønden A; Knop FK; Christensen MB
Clin Pharmacokinet; 2017 Jul; 56(7):719-731. PubMed ID: 28050889
[TBL] [Abstract][Full Text] [Related]
26. Albiglutide: a review of its use in patients with type 2 diabetes mellitus.
Blair HA; Keating GM
Drugs; 2015 Apr; 75(6):651-63. PubMed ID: 25777969
[TBL] [Abstract][Full Text] [Related]
27. Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program.
Davidson JA; Jones-Leone A; Wilson TH; Nino A; Forero-Schwanhaeuser S; Reinhardt RR
Postgrad Med; 2017 Nov; 129(8):849-857. PubMed ID: 29083275
[TBL] [Abstract][Full Text] [Related]
28. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial.
Østoft SH; Bagger JI; Hansen T; Pedersen O; Faber J; Holst JJ; Knop FK; Vilsbøll T
Diabetes Care; 2014 Jul; 37(7):1797-805. PubMed ID: 24929431
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.
Leiter LA; Carr MC; Stewart M; Jones-Leone A; Scott R; Yang F; Handelsman Y
Diabetes Care; 2014 Oct; 37(10):2723-30. PubMed ID: 25048383
[TBL] [Abstract][Full Text] [Related]
30. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing.
Rosenstock J; Reusch J; Bush M; Yang F; Stewart M;
Diabetes Care; 2009 Oct; 32(10):1880-6. PubMed ID: 19592625
[TBL] [Abstract][Full Text] [Related]
31. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Trujillo JM; Nuffer W
Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
[TBL] [Abstract][Full Text] [Related]
32. Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.
Farngren J; Persson M; Ahrén B
Diabetes Care; 2016 Feb; 39(2):242-9. PubMed ID: 26537183
[TBL] [Abstract][Full Text] [Related]
33. Relative roles of insulin and hypoglycaemia on induction of neuroendocrine responses to, symptoms of, and deterioration of cognitive function in hypoglycaemia in male and female humans.
Fanelli C; Pampanelli S; Epifano L; Rambotti AM; Ciofetta M; Modarelli F; Di Vincenzo A; Annibale B; Lepore M; Lalli C
Diabetologia; 1994 Aug; 37(8):797-807. PubMed ID: 7988782
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the counter-regulatory responses to hypoglycaemia in patients with type 1 diabetes during opiate receptor blockade with naltrexone.
Naik S; Belfort-DeAguiar R; Sejling AS; Szepietowska B; Sherwin RS
Diabetes Obes Metab; 2017 May; 19(5):615-621. PubMed ID: 27987236
[TBL] [Abstract][Full Text] [Related]
35. Similar physiological and symptomatic responses to sulphonylurea and insulin induced hypoglycaemia in normal subjects.
Peacey SR; George E; Rostami-Hodjegan A; Bedford C; Harris N; Hardisty CA; Tucker GT; Macdonald IA; Heller SR
Diabet Med; 1996 Jul; 13(7):634-41. PubMed ID: 8840097
[TBL] [Abstract][Full Text] [Related]
36. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
Degn KB; Juhl CB; Sturis J; Jakobsen G; Brock B; Chandramouli V; Rungby J; Landau BR; Schmitz O
Diabetes; 2004 May; 53(5):1187-94. PubMed ID: 15111485
[TBL] [Abstract][Full Text] [Related]
37. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
Clark HE; Matthews DR
Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
[TBL] [Abstract][Full Text] [Related]
38. Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemic euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemia.
Porcellati F; Pampanelli S; Rossetti P; Busciantella Ricci N; Marzotti S; Lucidi P; Santeusanio F; Bolli GB; Fanelli CG
Diabetologia; 2007 Feb; 50(2):422-30. PubMed ID: 17160672
[TBL] [Abstract][Full Text] [Related]
39. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study.
Deane AM; Chapman MJ; Fraser RJ; Burgstad CM; Besanko LK; Horowitz M
Crit Care; 2009; 13(3):R67. PubMed ID: 19439067
[TBL] [Abstract][Full Text] [Related]
40. [Albiglutide (Eperzan): a new once-weekly agonist of glucagon-like peptide-1 receptors].
Scheen AJ
Rev Med Liege; 2015 Apr; 70(4):207-14. PubMed ID: 26054173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
